DCTD’s Translational Research Program Announces Fiscal Year 2025 SPORE Grantees
- Posted:
The Translational Research Program (TRP) recently announced its successfully competed FY2025 Specialized Programs of Research Excellence (SPORE) grantees.
The SPORE program uses the P50 and U54 grant funding mechanisms to promote collaborative, interdisciplinary, translational cancer multi-project research. SPOREs are primarily focused on organ site disease, but also on themes that cut across organ sites.
There are now 56 funded SPOREs, including traditional P50 SPORE grants as well as the U54 RFA SPORE awards in Cancer Health Disparities, located at academic centers in 32 states.
FY 2025 SPORE Grantees
| Principal Investigator | Institution | Cancer Type |
|---|---|---|
| Isabella Rosa-Cunha; Erin Kobetz; Lisa Flowers and James Lillard | University of Miami, Emory University, and Morehouse School of Medicine | Anal and Cervical |
| *Kornelia Polyak; Leif Ellisen; Nancy Lin; Geoffrey Shapiro | Dana-Farber Cancer Institute and Harvard Cancer Center | Breast |
| Victoria Bae-Jump and Hazel Nichols | University of North Carolina, Chapel Hill | Endometrial |
| *Robert Coffey | Vanderbilt University Medical Center | Gastrointestinal |
| Monica Gramatges; Philip Lupo and Karen Rabin | Baylor College of Medicine, Emory University and University of California, San Francisco | Leukemia |
| Amit Singal and Yujin Hoshida | University of Texas Southwestern Medical Center | Liver |
| *Roy Herbst and Katerina Politi | Yale University | Lung |
| *A. McGarry Houghton | Fred Hutchinson Cancer Research Center | Lung |
| Christopher Flowers and Jean Koff | University of Texas MD Anderson Cancer Center and Winship Cancer Institute of Emory University | Lymphoma |
| Susan Chang and Franklin Huang | University of California, San Francisco | Meningioma, Prostate, and Breast |
| Dawn Quelle; James Howe and Yusuf Menda | University of Iowa | Neuroendocrine Tumors |
| *Arul Chinnaiyan and Ganesh Palapattu | University of Michigan, Ann Arbor | Prostate |
| Richard Gorlick and Phillip Futreal | University of Texas MD Anderson Cancer Center | Sarcoma |
*Grant Renewal
Goals of the SPORE Program
- Translating novel scientific discoveries from the laboratory and/or population studies to the clinic for testing in humans with cancer or at risk for cancer
- Determining the biological basis for clinical observations
- Using specimens from clinical studies to determine correlations between biomarkers and outcomes in patients
- Promoting collaborations between SPOREs, Cancer Centers, other NCI/NIH funded mechanisms and programs, and outside organizations
- Promoting pilot projects and career enhancement of researchers new to translational research
- Supporting research in high incidence and rare cancers
- Encouraging communication with advocates and advocate organizations to obtain advice from the patient perspective
Contact TRP staff for more information on the SPORE program.